Ardent Health, Inc. 8-K

What Happened Ardent Health, Inc. announced on June 2, 2026 that its Board appointed Dave Caspers (age 55), previously the Company’s Chief Operating Officer, as President and Chief Executive Officer and as a director, effective June 2, 2026. Mr. Caspers succeeds Martin J. Bonick, who separated from the company and stepped down from the Board effective the same date. The company filed an employment agreement for Mr. Caspers and issued a press release announcing the leadership change.

Key Details

• Employment term: initial term through May 31, 2029 with automatic one-year renewals unless timely non-renewed.
• Pay and bonus: base salary of $900,000; eligible for annual bonus with a 2026 target opportunity of 105% of base salary.
• Severance: if terminated for Good Reason or without Cause (not for death/Disability), Caspers is eligible for cash severance equal to 2x (salary + target bonus) and up to 18 months of health/dental/vision premium reimbursement; during the six months before through 18 months after a Change in Control the severance is 3x (salary + target bonus) plus up to 18 months of coverage. Payments generally paid over 24 months (or lump sum on Change in Control) conditioned on a release.
• Equity awards: one-time time-based RSUs worth $1,050,000 vesting in three equal annual installments; one-time performance RSUs with a $1,950,000 target value tied to 2026 adjusted EBITDAR and net revenue performance (0–200% payout, with at least 33% of target payable) and modified by relative TSR (+/− up to 25%), vesting by April 1, 2029. Employment agreement (Exhibit 10.1) filed with the 8-K.
• Restrictions: perpetual confidentiality obligation and 24-month post-employment non-compete and non-solicit restrictions. Company will disclose any finalized separation agreement and related arrangements for Mr. Bonick in a later filing.

Why It Matters A CEO change is a material governance event that can affect company strategy, operations and investor expectations. The filing details Mr. Caspers’ compensation, incentive structure and protections (severance and equity), which indicate the board’s alignment and retention priorities for the new leader. Investors should note the sizable equity grants and performance metrics that tie pay to revenue, adjusted EBITDAR and relative total shareholder return, and watch for any future disclosure about Mr. Bonick’s separation terms.